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Abstract. In this experiment we studied oncologic safety of model implants created using the solution blow spinning 
method with the use of the PURASORB PL-38 polylactic acid polymer and organic mineral filler which was obtained via 
laser ablation of a solid target made of dibasic calcium phosphate dihydrate. For this purpose the implant was introduced 
into the area of Wistar rats’ iliums, and on day 17 after the surgery the Walker sarcoma was transplanted into the area of 
the implant. We evaluated the implant’s influence on the primary tumor growth, hematogenous and lymphogenous 
metastasis of the Walker sarcoma. In comparison with sham operated animals the implant group demonstrated significant 
inhibition of hematogenous metastasis on day 34 after the surgery. The metastasis inhibition index (MII) equaled 94% 
and the metastases growth inhibition index (MGII) equaled 83%. The metastasis frequency of the Walker sarcoma in para 
aortic lymph nodes in the implant group was not statistically different from the control frequency; there was also no 
influence of the implant on the primary tumor growth noted. In case of the Walker sarcoma transplantation into the calf 
and the palmar pad of the ipsilateral limb to the one with the implant in the ilium, we could not note any attraction of 
tumor cells to the implant area, i.e. stimulation of the Walker sarcoma relapse by the implant. Thus, the research 
concluded that the studied implant meets the requirements of oncologic safety. 
INTRODUCTION 
The main goals of today’s reconstructive surgery are recovery of formations lost due to cancer or damaged ones, 
achieving acceptable post-surgery cosmetic and functional results that ensure sufficient quality of a patient’s life. 
The most important anatomic sites are the skullcap, facial skeleton, respiratory passages and chest wall [1]. The 
enumerated anatomic zones possess a common structure component, the carcass which is different depending on its 
location, stiffness, configuration and thickness. Reconstruction of such formations involves complex surgical 
methods including autogenous tissue complex transplantation; duration of such surgery is long and the procedure is 
multiphase [1, 2]. At the current stage of reconstructive surgery the need for creating and implementing synthetic 
and composite tissue replacement materials is becoming more and more apparent. An implant should fit the shape, 
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volume, structure, texture of the tissue, and the function of the recovering organ [3]. New tissue replacement 
systems should combine strong integration potential with longevity in aggressive environment and ability to be filled 
with medicine to regulate tissue reaction [3, 4]. Creation and preclinical study of new types of stented composite 
implants, which are strong and can preserve their shape, and bioactive coating (polymer material) that enhances the 
integration of an implant are undoubtedly essential and timely. 
Reconstructive surgery on oncology patients requires implants to be one more thing—oncologically safe, i.e. it 
must not possess features that would stimulate relapse of carcinomas in a recipient’s tissue that contacts the implant 
and distant metastases. The problem is long-lasting chronic inflammation around an implant in the area of a 
removed tumor, it may lead to local relapse and/or stimulate the development of metachronous tumor nidus or 
distant metastases, i.e. progress of the process [5], thus jeopardizing the results of antitumor treatment. For that 
matter the stage of preclinical study of implants for oncology patients is essential; it is especially important to study 
the influence of such implants on the growth and metastasis of experimental tumors. 
While completing the 1st stage of a federal program “Research and inventions within priority areas of 
development of Russian scientific and technological complex for years 2014–2020” (Agreement No. 14.578.21. 
0031) a primary screening of integration features was performed for several polymer-based (polylactic acids) 
bioactive coatings with different organic mineral filling obtained via laser ablation: dibasic calcium phosphate 
dihydrate (CaHPO4·2H20, DCPD) and hydroxyapatite (Ca10(PO4)6(OH)2, HAP).  
We have determined that the materials obtained via laser ablation of a dicalcium phosphate (CaHPO4) solid 
target is not toxic and provides high adhesion of stem cells [6], which was the reason DCPD was chosen to be 
studied in terms of oncologic safety. 
The aim of the research is to study the influence of composite implants based on biodegradable polymer 
(polylactic acid) and an organic mineral filling (DCPD) on the growth, metastasis and relapse of the Walker sarcoma 
in rats. 
MATERIAL AND METHODS 
Implant
The experiment involved dummy implants made via “solution blow spinning” (SBS) method [7, 8] based on 
polylactic acid (PURASORB PL-38) and organic mineral filling obtained via laser ablation of a DCPD solid target. 
Macroscopically the implants are 10×10 mm fragments of the material that resembles “filtered paper”. The 
fragments molded easily while being implanted, did not break, demonstrated good adhesion to the surrounding soft 
tissue (due to the capillary effect). 
Animals 
40 Wistar male rats weighing 180–200 g and bred by Scientific and Research Institute of Pharmacology and 
Regenerative Medicine named after E.D. Goldberg were used for the research. The experiments were performed in 
compliance with humanity principles according to the Rules of work using experimental animals (an act by the 
Ministry of Healthcare of the USSR from August 12th, 1977) and the principles expressed in the guidelines by the 
European Community (86/609/???) and the Declaration of Helsinki. The animals were kept according to Methodic 
recommendations of keeping laboratory animals in vivariums of scientific and research institutions and educational 
institutions (Ruling Documents 3.10.07.02-09) by the Ministry of Agriculture of the Russian Federation with the 
standard vivarium nutrition and free access to feed and drinking water (tap water with quality in compliance with  
Sanitary Regulations and Standards 2.1.4.1074-01). The animals were kept under artificial and natural lighting 
according to the requirements of Construction Rules and Regulations 23.05-95 and Industry Construction Standards 
2.10.24.001-04. 
Implantation of Samples 
The material was implanted under general mixed anesthesia (the dosage is calculated depending on an animal’s 
weight): Zoletil (5–7 mg/kg) and Rometar (4 mg/kg) intramuscularly. After medication sleep started, we prepared 
the surgical site: we removed body hair in the area of the animal’s pelvis (3×4 cm) with a Moser 1584-0050 Li+Pro 
Mini trimmer (USA). The animals were on the table in the belly-down position. The surgical site was antisepticized 
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with a solution of a Septocide R skin antiseptic. The surgical procedures were performed using surgical tools 
sterilized via autoclaving (Sanitary Regulations and Standards 2.1.3.2630-10). 
The ilium was accessed via a 12–20 mm longitudinal cut. Each animal was implanted one sterile sample of the 
same type with the size of 7–9 mm in the projection of the ilium. Before the procedure we gained subperiosteal 
access to the inner surface of the ilium, moreover, we performed scarification of cortical plate with a sharp raspatory. 
The samples were implanted on the scarified bone surface. The implants were fixed with muscular tissue returned to 
its original place. The control group animals underwent identical procedures except for the sample implantation. 
Design of Research 
4 groups of animals were formed for the research: 1st—the control group (10 animals underwent sham surgery 
and on the day 17 300 mcl of the Walker carcinoma cells suspension were transferred to the surgical site of the 
ipsilateral paw); 2nd group—experiment 1 (10 animals had a sample implanted and on day 17 300 mcl of the Walker 
carcinoma cells suspension were transferred to the implant site of the ipsilateral paw); 3rd group—experiment 2 
(10 animals had a sample implanted and on day 17 300 mcl of the Walker carcinoma cells suspension were 
transferred to the calf of the ipsilateral paw); 4th group—experiment 3 (10 animals had a sample implanted and on 
day 17 100 mcl of the Walker carcinoma cells suspension were transferred to the plantar pad of the ipsilateral paw). 
The animals of the control and the 1st groups were evaluated in terms of the implant influence on the primary 
tumor growth, haematogenous and lymphogenous metastasis of the Walker sarcoma. The influence of the implant 
on the primary tumor was evaluated by comparing the rates of tumor growth in control and experiment groups. To 
do so, from day 7 the diameter of the tumor node was being measured in 3 mutually perpendicular directions. Tumor 
volume was calculated as follows: 6V ABC? ? , where A, B, C are diameters of the tumor node in 3 mutually 
perpendicular directions [9]. 
On day 34 after the surgery or day 17 after the tumor transplantation the rats were euthanized under anesthesia 
(toxic dosage of Zoletil of 35–40 mg/kg) and the tumors weight was estimated for each animal. After dissection the 
lungs and par aortic lymph nodes were extracted. The influence of an implant on metastasis of the Walker sarcoma 
was evaluated based on metastasis frequency, number of metastases in the lungs and their area, moreover, metastasis 
frequency and metastases weight in the par aortic lymph nodes were evaluated. The metastasis inhibition index was 
calculated as follows: sham sham exp exp
sham sham
IIM 100%,
A B A B
A B
?? ?  where A is the percentage for rats with metastases, B is 
the number of metastases. The metastases growth inhibition index was evaluated as well based on the total area (S) 
of metastases according to the following formula: sham exp
sham
MGII 100%,
S S
S
?? ?? ??  where shamS?  is the total area 
of metastases in the control group; expS?  is the total area of metastases in the experiment group [10]. 
In order to assess the influence of the implant on the Walker sarcoma relapse in rats of the 2nd and 3rd groups, 
on day 17 after the tumor transplantation we took tissue from the area of the implant for a histological study. By 
doing so we also determined the presence of tumor cells in the area of the implant which could have come there 
from the primary site in the calf or a pad of the ipsilateral paw. To gather material for morphological examination 
we removed fragments of the ilium with the adjacent implant and muscular tissue covering the bone. Samples of the 
tissue together with the implant were placed in vials with neutral formalin solution. The ratio of the fixing fluid to 
the sample equaled 20 : 1. 
Preparation of Histological Specimen 
The tissue fixed in 10% formalin for at least 1 day. The samples with bone tissue were decalcified in the mixed 
formic acid and 10% formalin solution with the 1 : 4 ratio. The time for decalcification was 5–7 days. After this the 
tissue was dehydrated and soaked in paraffin wax in a Leica ASP-300S tissue processor. Further the material was 
mounted on cassettes. Sections of about 5–7 ?m thick were prepared on a Leica RM 2255 rotary microtome, 
mounted on the slide and dyed with hematoxylin and eosin in a Thermo Gemini AS histology slide stainer. The 
microscopic evaluation was performed with a Zeiss Axio Scope optical microscope (Germany) with the zoom from 
×50 to ×100. 
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(a) (b) 
FIGURE 1. SEM images of implanted materials 
Statistical Analysis 
Statistical analyses were performed using STATISTICA 8.0 software (StatSoft, Tulsa, OK, USA). The arithme-
tic mean value and standard error were calculated for each sample group, and Mann-Whitney U-test was applied to 
identify the link the volume and weight of primary tumor and lymph node metastases between control and 
experimental 1st groups. A two-sided p-value was calculated using Fisher’s exact test http://vassarstats.net/odds2x2. 
html. Differences were significant if the p value was less than 0.05. 
RESULTS AND DISCUSSION 
The images of materials for implantation are presented in the Fig. 1. Formed material (Fig. 1a) possesses fiber 
pattern with bimodal distribution of the fibers on the diameter, which is common for materials formed via SBS 
method [11]. Particles of mineral filling in the material are situated on the surface of the fibers. At the same time, 
big particles are situated in the space between fibers (Fig. 1b). 
The formed material possesses high interconnected porosity, which allows normal metabolism and eases the 
implant’s integration with the tissue. 
  
(a) (b) 
FIGURE 2. Macroscopic (a) and microscopic (b) preparations of implant region: 1—bone tissue, 2—the remaining part of the 
implant, 3—inflammatory infiltrate, 4—muscular tissue; image zoomed in ×100, decalcification in formic acid, H&E staining 
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TABLE 1. Influence of the implant on the primary Walker sarcoma tumor node in rats 
Day after tumor transplantation 7 10 13 17 
SHAM 18.6 ± 2.3 35.1 ± 5.6 58.3 ± 4.3 70.8 ± 4.5 Volume tumor 
M ± SE, sm3 Experiment 1 17.6 ± 2.8 38.6 ± 6.4 60.8 ± 4.8 67.6 ± 5.4 
p-value 0.886 0.663 0.845 0.532 
SHAM 289.2 ± 32.2 309.6 ± 20.6 326.2 ± 16.6 334.2 ± 17.4 Weight of rate with 
tumor M ± SE, g Experiment 1 287.4 ± 14.3 306.4 ± 19.4 319.1 ± 12.7 331.5 ± 19.3 
p-value 0.931 0.643 0.451 0.478 
SHAM – – – 41.3 ± 3.4 Weight of primary 
tumor M±SE, g Experiment 1 – – – 41.7 ± 4.2 
p-value – – – 0.786 
 
Macroscopically, on day 15 after the surgery the implant visualized well within the surrounding muscular tissue 
in the form of a cloudy fragment (Fig. 2a). The implants were fixed to the surrounding muscular tissue and 
periosteal coverage well due to budding with connective tissue.  
The connective tissue capsule was transparent and soft. Microscopic examination on day 15 after the surgery 
showed that the material was mostly solid, but there was a tendency for microsequestration along the perimeter. 
There was an expressed giant cell reaction. Macrophage/histiocytic and fibroblastic reactions prevailed. There was a 
spread of infiltrate onto bone sinuses (Fig. 2b). We also noted the formation of a thicker layer of infiltrate on the side 
of the muscular tissue and its lesser presence on the side of the bone tissue. Such an observation means there was a 
positive tendency to integration of the studied samples with the bone tissue. 
Thus, by the time of tumor transplantation on day 17 after the surgery the implant was integrated into the 
surrounding tissue and there was an expressed reaction of the animals’ organisms to it in the form of inflammatory 
giant cell infiltrate with histiocytes and fibroblasts. 
The study of the influence on the rate of the primary tumor growth by the implant showed that neither volume of 
tumor node, nor mass of the body with a tumor, nor mass of the tumor on day 17 after transplantation were 
statistically different for sham operated animals and the 1st experiment group (Table 1). The animals did not have 
cachexia during the experiment. 
Frequency of the Walker sarcoma metastasis into para aortic lymph nodes for the implant group was not 
statistically different from the control group. Half of the animals in the control group had metastases in their lymph 
nodes, as only 30% of the experiment group animals had those (p = 0.325 F-test). The average mass of para aortic 
lymph nodes in the control group equaled 548 ± 119 mg, the same in the experiment group equaled 409 ± 91 mg 
(? = 0.212, Mann-Whitney U-test). 
The influence of the implant on the hematogenous metastasis of the Walker sarcoma was studied. The frequency 
of metastases in lungs of the control group animals equaled 70% (7/10) and averaged 4.8 metastases per rat. As for 
the experiment group, only 2 (2/10—20%) animals had metastases in their lungs and the average number of 
metastases per rat in the group equaled 1 (OR(95CI) = 0.10 (0.01–0.83)p = 0.035 F-test). Thus, the rats with 
implants had reduced frequency (lesser percentage of the animals with metastases) and intensity (the average 
number of lung metastases per rat) of metastasis. The metastasis inhibition index (MII) equaled 94%. The data 
showed expressed cytotoxic effect, i.e. prevention of metastasis in the group with implants. At the same time this 
group also showed significant reduction in the total area of metastatic colonies in lungs (27.284 mm2 for the control 
group and 4.609 mm2 in the experiment group) and high metastasis growth inhibition index (MGII) equaling 83%, 
which proves cytotoxic effect to be in place—the presence of the implant in an animal’s body helps inhibit the 
growth of already existing metastases. Having an implant “protects” an organism of the tumor bearer from 
metastases development. Apparently, the expressed inflammatory giant cell reaction to the implant encourages 
antimetastatic activation of the immune system. 
The last stage was to evaluate influence of the implant on the Walker sarcoma relapse. The tumor was 
transplanted into the ipsilateral paw remotely from the implant (into the calf and a pad). 
On day 17 after transplantation tumor samples (Fig. 3a) and implant samples (Fig. 3b) were taken for a 
microscopic examination. We determined that all 20 animals of the 2nd and 3rd experiment groups had no tumor 
cells in the area of the implant. 
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(a) (b) 
FIGURE 3. Transfer of tumor into the calf of limb ipsilateral with the implant: (a) the tumor tissue, zoomed in ×200; (b) the 
inflammatory infiltrate with a big number of giant cells of “foreign bodies”, among its cell elements there are no tumor cells, 
zoomed in ×200, preparation b is prepared after decalcification in formic acid, H&E stained 
 
Thus, the presence of an implant in the area of the ilium did not attract tumor cells for at least 17 days after 
tumor transplantation into an ipsilateral limb, i.e. the implant did not stimulate the Walker sarcoma relapse. 
The performed research showed that transplantation of composite implants based on biodegradable polymer 
(polylactic acid) and an organic mineral filling obtained via laser ablation of a solid DCPD target did not influence 
the primary Walker sarcoma tumor node growth and lymphogenic metastasis, did not stimulate relapse and provided 
significant antimetastatic effect on hematogenous metastasis. We can conclude that this implant meets the 
requirements of oncologic safety. 
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